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Summary
 
The importance of B7 costimulation in regulating T cell expansion and peripheral tolerance
suggests that it may also play a significant regulatory role in the development of autoimmune
disease. It is unclear whether B7 costimulation is involved only in the expansion of autoreac-
tive T cells in the periphery, or if it is also required for effector activation of autoreactive T cells
in the target organ for mediating tissue injury and propagating autoimmune disease. In this
study, the role of B7–CD28 costimulation and the relative importance of B7 costimulators for
the induction and effector phases of experimental autoimmune encephalomyelitis (EAE) in-
duced by myelin oligodendrocyte glycoprotein (MOG) peptide were examined. Wild-type,
B7-1/B7-2–deficient mice, or CD28-deficient C57BL/6 mice were immunized with MOG
35-55 peptide. Mice lacking both B7-1 and B7-2 or CD28 showed no or minimal clinical
signs of EAE and markedly reduced inflammatory infiltrates in the brain and spinal cord. How-
ever, mice lacking either B7-1 or B7-2 alone developed clinical and pathologic EAE that was
comparable to EAE in wild-type mice, indicating overlapping functions for B7-1 and B7-2.
Resistance to EAE was not due to a lack of induction of T helper type 1 (Th1) cytokines, since
T cells from B7-1/B7-2
 
2
 
/
 
2
 
 mice show reduced proliferative responses, but greater interferon 
 
g
 
production compared with T cells from wild-type mice. To study the role of B7 molecules in
the effector phase of the disease, MOG 35-55–specific T lines were adoptively transferred into
the B7-1/B7-2
 
2
 
/
 
2
 
 and wild-type mice. Clinical and histologic EAE were markedly reduced in
B7-1/B7-2
 
2
 
/
 
2
 
 compared with wild-type recipient mice. These results demonstrate that B7 co-
stimulation has critical roles not only in the initial activation and expansion of MOG-reactive
T cells, but also in the effector phase of encephalitogenic T cell activation within the central
nervous system.
Key words: B7 • costimulation • knockout mouse • autoimmunity • experimental 
autoimmune encephalomyelitis
 
T
 
he B7-CD28/CTL-associated molecule 4 (CTLA-4)
 
1
 
costimulatory pathway plays a pivotal role in regulat-
ing T cell activation and peripheral tolerance and is a
promising therapeutic target for treating inflammatory au-
toimmune diseases. The B7 family of costimulatory mole-
cules, B7-1 (CD80) and B7-2 (CD86), provide the major
costimulatory signal for augmenting and sustaining T cell
responses via ligation of the CD28 receptor. B7–CD28 in-
teractions regulate T cell growth, survival, and differentia-
tion. The B7 family of costimulators also bind a second
higher affinity receptor on T cells, CTLA-4 (CD152). B7–
CTLA-4 interactions provide a critical downregulatory sig-
nal for T cell activation, which may regulate autoreactive T
cells in the periphery (1).
Studies using B7 antagonists have demonstrated the im-
portance of this pathway in the pathogenesis of autoim-
mune disease. B7 blockade can prevent the development of
experimental autoimmune encephalomyelitis (EAE), a T
cell–mediated autoimmune disease that shares many clinical
and histological features with multiple sclerosis (MS). Sev-
eral studies using SJL mice have shown that EAE in this
strain can be blocked by administering antibodies to B7-1
but not B7-2 (2–4). Such results led to the suggestion that
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; CTLA-4,
CTL-associated molecule 4; EAE, experimental autoimmune encephalo-
myelitis; MOG, myelin oligodendrocyte glycoprotein. 
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B7-1 is the more important costimulatory molecule in
EAE. However, whether B7-1 is also important in the in-
duction of disease in other EAE-susceptible strains and whether
the effect of anti-B7 mAbs was due to B7-1 blockade or ac-
tivation of B7-1–expressing cells has not been established.
One of the studies suggested that B7-1 versus B7-2 block-
ade may differentially affect T cell differentiation and Th1/
Th2 cytokine balance (3), whereas another study showed
that B7-1 becomes a dominant costimulatory molecule
during EAE (4). Therefore, the mechanisms by which B7-1
blockade protect against induction of EAE remain unclear.
B7 costimulation is potentially important in regulating T
cell function at several stages of EAE. These include the
initial activation, expansion, and differentiation of T cells
within peripheral lymphoid tissues, homing and entry into
the central nervous system (CNS), and reactivation of au-
toreactive T cells within the CNS that mediate tissue in-
jury. To further dissect the relative importance of B7 co-
stimulation for the induction and effector phases of EAE,
we induced EAE in C57BL/6 mice lacking B7 costimula-
tors (B7-1/B7-2
 
2
 
/
 
2
 
) or CD28 (CD28
 
2
 
/
 
2
 
). We compared
EAE induced by active immunization with myelin oligo-
dendrocyte glycoprotein (MOG) 35-55 peptide or adop-
tive transfer of MOG 35-55–specific T cells. Our results
demonstrate that B7 costimulation plays a critical role not
only in the induction phase of the autoimmune response
when T cells become activated in the periphery, but also in
the effector phase when potentially pathogenic T cells infil-
trate the target organ and mediate disease.
 
Materials and Methods
 
Mice
 
B7-1
 
2
 
/
 
2
 
, B7-2
 
2
 
/
 
2
 
, and B7-1/B7-2
 
2
 
/
 
2
 
 mice were generated
by gene targeting as described previously (5, 6). B7-deficient
mice were backcrossed from the 129/S4SvJae background to the
C57BL/6 background for at least six generations before use in
experiments, and were genotyped as described previously (5, 6).
CD28
 
2
 
/
 
2
 
 mice were purchased from The Jackson Laboratory.
Mice used for controls were either wild-type or heterozygous lit-
termates or C57BL/6 mice purchased from The Jackson Labora-
tory. Brigham and Women’s Hospital and Harvard Medical
School are accredited by the American Association of Laboratory
Animal Care (AALAC). Mice were cared for in accordance with
institutional guidelines in a pathogen-free animal facility.
 
MOG Peptide
 
MOG 35-55 (MEVGWYRSPFSRVVHLYRNGK) and MOG
92-106 (DEGGYTCFFRDHSYQ) were synthesized by Dr.
David Teplow at the Biopolymer Facility (Center for Neurologi-
cal Diseases, Brigham and Women’s Hospital) on an Applied
Biosystems 430A peptide synthesizer using fluorenylmethoxycar-
bonyl (F-MOC) chemistry. The peptides were 
 
.
 
90% pure, as
determined by HPLC.
 
Induction and Assessment of EAE
 
By Active Immunization.
 
Groups of 6–8-wk-old female mice
(three to six per group) were immunized with 100 
 
m
 
g of MOG
35-55 emulsified 1:1 in CFA supplemented with 400 
 
m
 
g of 
 
Myco-
bacterium tuberculosis
 
 H37RA (Difco Laboratories) in the two
flanks subcutaneously. 200 ng of pertussis toxin (List Biological
Laboratories) was injected intravenously on the day of immuniza-
tion and 2 d later.
 
By Adoptive Transfer.
 
Wild-type mice were immunized with
100 
 
m
 
g of MOG 35-55 in CFA (Difco Laboratories). 10 d later,
draining lymph nodes were harvested, and lymphocytes were
cultured with 30 
 
m
 
g of MOG 35-55 and 20 ng of murine rIL-12
(Genetics Institute). After 4 d of culture, cells were washed and
resuspended in PBS for transfer. Wild-type or B7-1/B7-2
 
2
 
/
 
2
 
 re-
cipients received 10
 
7
 
 cells intravenously, as well as 200 ng of per-
tussis toxin immediately after cell transfer and 2 d later.
Mice were observed daily for clinical signs of EAE up to 35 d
after immunization or cell transfer, and scored on a scale of 0–5:
0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb pa-
ralysis; 4, hind and fore limb paralysis; and 5, moribund state.
Mean clinical score was calculated by averaging the scores of all
mice in each group, including animals that did not develop EAE.
 
Histology
 
Brains and spinal cords were removed and fixed in 10% forma-
lin. Paraffin-embedded sections were stained with Luxol fast
blue–hematoxylin and eosin for light microscopy. Inflammatory
foci were counted in the meninges and parenchyma by an unbi-
ased observer as described previously (7).
 
Proliferative Response of T Cells to MOG Antigens
 
Mice were immunized subcutaneously with 100 
 
m
 
g of MOG
35-55 emulsified 1:1 in CFA (Difco Laboratories). Draining
lymph nodes were harvested 10 d later, and single cell suspen-
sions were prepared. Whole lymph node cells were cultured in
96-well plates at 5 
 
3 
 
10
 
5
 
 cells/well with a range of concentra-
tions of MOG 35-55 or MOG 92-106 peptide in HL-1 media
(BioWhittaker). Plates were pulsed with [
 
3
 
H]thymidine (New
England Nuclear) at 1 
 
m
 
Ci/well on day 3 of culture for the final
18 h. Mean incorporation of thymidine in DNA was measured in
triplicate wells by liquid scintillation counting (model LS 5000;
Beckman Instruments).
 
Cytokine ELISA
 
Lymph node cells were prepared and cultured as above with
media alone or 50 
 
m
 
g of MOG 35-55 peptide. Supernatants were
harvested at 24, 48, and/or 72 h of culture. Cytokines (IL-2,
IFN-
 
g
 
, TNF-
 
a
 
, IL-4, and IL-10) were determined by sandwich
ELISA, as described (8). mAb pairs and recombinant cytokine
standards were purchased from PharMingen. The following mAb
pairs were used: IL-2 (JES6-1A12, capture; JES6-5H4 detection);
IFN-
 
g
 
 (R4-6A2 capture; XMG1.2 detection); IL-4 (BVD4-
1D11 capture; BVD6-24G2 detection); IL-10 (JES5-2A5 cap-
ture; SXC-1 detection); and TNF-
 
a
 
 (G281-2626 capture; MP6-
XT3 detection).
 
Results
 
Mice Lacking Both B7-1 and B7-2 or CD28 Are Resistant
to EAE Induced by Immunization with MOG 35-55.
 
To ex-
amine the role of the B7–CD28 costimulatory pathway in
the initiation of MOG-induced EAE, we immunized wild-
type C57BL/6 mice and C57BL/6 mice lacking CD28 or
either B7-1 or B7-2 or both B7 costimulators with MOG
35-55 and observed the mice for clinical signs of EAE. 
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Mice deficient in either B7-1 or B7-2 developed EAE with
comparable severity and time course to wild-type mice
(Fig. 1, A and B). EAE incidence, time of onset, and maxi-
mal clinical score were not significantly different among
wild-type, B7-1
 
2
 
/
 
2
 
, and B7-2
 
2
 
/
 
2
 
 mice (Table I). All three
groups had 
 
.
 
90% clinical disease incidence. EAE onset oc-
curred 13–16 d after immunization and reached maximal
severity at a clinical score of 2.5–3.0 (severe hind limb
weakness or paralysis). These results indicate that the pres-
ence of either B7-1 or B7-2 alone is sufficient to provide
the costimulation necessary to support the development of
MOG-induced EAE in C57BL/6 mice.
In contrast, mice lacking both B7-1 and B7-2 were
strikingly resistant to EAE induction (Fig. 1 C). In 3 sepa-
Figure 1. EAE disease course in
C57BL/6 B7-12/2 mice (A; n 5
34), B7-22/2 mice (B; n 5 22),
B7-1/B7-22/2 mice (C; n 5 18),
and CD282/2 mice (D; n 5 13).
Filled diamonds in A–D, wild-
type (Wt) mice. Mice were im-
munized with 100 mg of MOG
35-55 subcutaneously and in-
jected twice with 200 ng of per-
tussis toxin intravenously. Mice
were observed daily and scored
as described in Materials and
Methods. Data are pooled from
three to five experiments and
represent mean clinical score of
each group plotted against time.
 
Table I.
 
EAE in Mice Lacking B7 Costimulators or CD28 Induced by Active Immunization
 
Clinical EAE
 
*
 
Histological EAE
Incidence
Day of
onset
Mean maximal
score Incidence
Meningeal
foci
Parenchymal
foci Total foci
 
mean 
 
6
 
 SE mean 
 
6
 
 SE mean 
 
6
 
 SE mean 
 
6
 
 SE mean 
 
6
 
 SE
 
Wild-type 27/29 15.8 
 
6
 
 0.9 3.0 
 
6
 
 0.2 18/21 21.7 
 
6
 
 7.0 15.7 
 
6
 
 5.0 37.4 
 
6
 
 11.9
(93.1%) (85.7%)
B7-1
 
2
 
/
 
2
 
31/34 14.6 
 
6
 
 0.5 2.9 
 
6
 
 0.1 21/23 14.2 
 
6
 
 3.4 13.0 
 
6
 
 3.2 27.2 
 
6
 
 6.4
(91.2%) (91.3%)
B7-2
 
2
 
/
 
2
 
21/22 13.9 
 
6
 
 1.0 2.4 
 
6
 
 0.2 21/21 29.1 
 
6
 
 5.4 9.4 
 
6
 
 2.0 38.9 
 
6
 
 7.0
(95.5%) (100.0%)
B7-1/B7-2
 
2
 
/
 
2
 
0/18 NA NA 7/14 12.8 
 
6
 
 7.3 0.6 
 
6
 
 0.4 13.3 
 
6
 
 7.4
(0.0%) (50.0%)
 
P
 
 
 
,
 
 0.001
 
P
 
 
 
,
 
 0.03
 
P
 
 
 
,
 
 0.0001
 
‡
 
P
 
 
 
5
 
 0.05
CD28
 
2
 
/
 
2
 
2/13 17.5 
 
6
 
 1.4 2.0 
 
6
 
 0.0 6/11 2.9 
 
6
 
 1.3 1.5 6 0.6 4.4 6 1.8
(15.4%) (54.5%) P , 0.01 P , 0.01 P , 0.01
P , 0.0001
*EAE was induced by immunization with 100 mg MOG 35-55 subcutaneously.
‡All P values are compared with wild-type.736 B7-deficient Mice and EAE
rate experiments involving 18 B7-1/B7-22/2 mice, none
of the B7-1/B7-22/2 mice developed clinical signs of EAE
during the 35-d observation period, whereas 90% of wild-
type littermates developed EAE. Similar to the B7-1/B7-
22/2 mice, mice lacking CD28 were also resistant to EAE
induction (Fig. 1 D). Only 2 of 13 (15%) CD282/2 mice
developed clinical signs of EAE. In these two CD282/2
mice, the time of onset of EAE was delayed, and the maximal
disease score was also less than in wild-type mice (Table I).
B7-1/B7-22/2 Mice and CD282/2 Mice Show Less CNS
Inflammation after MOG Peptide Immunization Than Wild-
type Mice. The brain and spinal cords of wild-type, B72/2,
and CD282/2 mice were examined histologically at the
end of the clinical observation period (day 35 after immu-
nization). Wild-type, B7-12/2, and B7-22/2 mice had sim-
ilar numbers of inflammatory lesions in the meninges and
CNS parenchyma (Fig. 2, A and B). More than 80% of
mice in each of these groups demonstrated inflammatory
lesions. In contrast, EAE inflammatory foci were observed
in approximately half of B7-1/B7-22/2 and CD282/2
mice, and the numbers of foci were significantly reduced in
both groups (Table I). Thus, the lack of clinical disease in
B7-1/B7-22/2 mice was accompanied by a marked reduc-
tion in CNS inflammation. Strikingly, in the seven B7-1/
B7-22/2 mice that exhibited inflammatory foci (Table I),
these foci were limited almost exclusively to the lepto-
meninges (Fig. 2 C). Thus, the absence of both B7-1 and
B7-2 resulted in a disproportionate reduction of parenchy-
mal compared with meningeal infiltrates.
B7-1/B7-22/2 T Cells Are Primed to MOG and Secrete
Abundant IFN-g. To determine whether the phenotype
of responding T cells to MOG 35-55 was altered in mice
lacking either or both B7 costimulators, we restimulated
draining lymph node cells with MOG 35-55 in vitro and
measured proliferative responses and cytokine secretion.
For these studies, draining lymph nodes were obtained 10 d
after immunization with MOG 35-55. Proliferation and
cytokine production were evaluated on days 1, 2, and 3 of
in vitro culture using a range of peptide concentrations. As
shown in Fig. 3, the proliferative responses of draining
lymph node cells obtained from immunized wild-type and
B7-12/2 mice were comparable. No consistent or signifi-
cant differences in IFN-g and TNF-a production were ob-
served in B7-12/2 lymph node cultures compared with
wild-type. Although the proliferative responses of B7-22/2
lymph node cells were modestly reduced at high peptide
concentrations, they produced more IFN-g than wild-type
cells (Fig. 3). IL-2, IL-4, and IL-10 were below detection
limit for all cultures. The modest differences in T cell pro-
liferation and cytokine production in B7-12/2 and B7-22/2
lymph node cultures are similar to the minimal variations in
clinical and histological manifestations of EAE among wild-
type, B7-12/2, and B7-22/2 mice.
In contrast, EAE-resistant B7-1/B7-22/2 mice exhibited
markedly impaired proliferative responses to MOG 35-55
compared with wild-type mice (Fig. 4). Even at the highest
peptide concentration examined, the proliferation of B7-1/
B7-22/2 lymph node cells was only 25% of wild-type lev-
els. Despite the reduced proliferation, B7-1/B7-22/2 lym-
phocytes produced significantly increased levels of IFN-g
(.30-fold increase) with faster kinetics. Although IFN-g
was detectable in wild-type cultures only after 48 h of stim-
ulation, IFN-g was present at high levels in B7-1/B7-22/2
cultures by 24 h. IFN-g production by B7-1/B7-22/2 cells
remained much higher than wild-type throughout the 3-d
culture period. TNF-a production was also increased in
B7-1/B7-22/2 cultures. However, in contrast to IFN-g,
B7-1/B7-22/2 lymphocytes secreted higher levels of TNF-a
only in the first 24 h of culture. By 48 h, TNF-a was de-
tectable in wild-type cultures while TNF-a production in
B7-1/B7-22/2 cultures had declined. IL-2, IL-4, and IL-10
were below detection limits. These results suggest that B7-
1/B7-22/2 T cells are primed to MOG 35-55 in vivo, but
that the expansion of these T cells is impaired. Further-
more, the increased levels of IFN-g and TNF-a in B7-1/
B7-22/2 lymphocyte cultures indicate that EAE resistance
in these mice is not likely to be due to a defect in Th1 cy-
tokine production.
B7-1/B7-22/2 Mice Show Markedly Reduced EAE after
Adoptive Transfer of Wild-type MOG-specific T Cells. To
Figure 2. CNS histopathology. Representative fields from the anterior lumbar spinal cord of wild-type (A), B7-22/2 (B), and B7-1/B7-22/2 (C) mice
from day 35 after immunization. In A and B, there are many mononuclear inflammatory cells in the leptomeninges and infiltrating the parenchyma. In C,
there is a small meningeal inflammatory focus (arrow), but the parenchyma is not infiltrated. All are stained with Luxol fast blue–hematoxylin and eosin.
Original magnifications: 2803.737 Chang et al.
evaluate whether B7 costimulation has a role in the effector
phase of EAE, wild-type MOG 35-55–specific T cells were
adoptively transferred into wild-type and B7-1/B7-22/2
mice. B7-1/B7-22/2 mice developed less severe EAE upon
adoptive transfer compared with wild-type (Fig. 5). EAE
onset was delayed in B7-1/B7-22/2 mice. Severity and du-
ration of clinical disease in B7-1/B7-22/2 mice was also
significantly reduced. Histologic evaluation demonstrated
that the B7-1/B7-22/2 recipient mice had fewer CNS in-
flammatory infiltrates compared with wild-type mice, with
a greater reduction of parenchymal compared with
meningeal foci (Table II). Thus, B7 costimulation is re-
quired both for the initiation and/or expansion of T cells in
the peripheral immune compartment and for the effector
Figure 3. Proliferation and cyto-
kine production of lymph node cells
from B7-12/2 and B7-22/2 mice
challenged with MOG 35-55. Mice
were immunized with 100 mg of
MOG 35-55 in CFA. 10 d later,
draining lymph node cells from
wild-type (Wt, diamonds), B7-12/2
(squares), or B7-22/2 (triangles)
mice were restimulated in vitro with
a titration of MOG 35-55 (filled
symbols) or MOG 92-106 (open
symbols) as control. Culture super-
natants were collected after 48 h
from cultures stimulated with 50
mg/ml of MOG 35-55 or with me-
dia alone. Cytokines were measured
by sandwich ELISA, and back-
ground levels from media controls
were subtracted. Data are represen-
tative of eight independent experi-
ments.
Figure 4. Proliferation and cyto-
kine production of lymph node cells
from B7-1/B7-22/2 mice chal-
lenged with MOG 35-55. Mice
were immunized with 100 mg of
MOG 35-55 in CFA. 10 d later,
draining lymph node cells from
wild-type (diamonds) or B7-1/B7-
22/2 (circles) mice were restimu-
lated in vitro with a range of MOG
35-55 peptide concentrations. Su-
pernatants were collected after 24,
48, and 72 h from cultures stimu-
lated with 50 mg/ml of MOG 35-55
or with media alone. Cytokines
from wild-type (Wt, solid bars) and
B7-1/B7-22/2 (hatched bars) cul-
tures were measured by sandwich
ELISA, and background levels from
media controls were subtracted.
Data are representative of eight in-
dependent experiments.738 B7-deficient Mice and EAE
phase of EAE to mediate tissue injury and enable disease
progression.
Discussion
In this study, we have examined the role of B7–CD28
costimulation and its relative importance for the induction
and effector phases of MOG-induced EAE using mice defi-
cient in B7 costimulators or CD28. We have demonstrated
that: (a) mice lacking either B7-1 or B7-2 develop EAE
comparably to wild-type mice; (b) mice lacking both B7-1
and B7-2 or CD28 are highly resistant to EAE induction;
(c) resistance to EAE is not due to a lack of Th1 cytokine
production; and (d) B7 costimulatory molecules are critical
for the effector phase of EAE, since EAE is markedly re-
duced in B7-1/B7-22/2 recipients after adoptive transfer of
MOG-specific wild-type T cells. Taken together, these re-
sults indicate that the B7–CD28 costimulatory pathway is
required for the development of MOG 35-55–induced
EAE in C57BL/6 mice. B7 costimulators have critical roles
both in the initial activation and expansion of MOG-reac-
tive T cells and in their activation within the target organ.
Our studies with mice lacking either B7-1 or B7-2 alone
demonstrate that B7-1 and B7-2 have overlapping roles in
MOG-induced EAE. This contrasts with EAE studies in
SJL mice in which in vivo administration of anti–B7-1 an-
tibodies reduced disease whereas anti–B7-2 antibodies ei-
ther had no effect or exacerbated disease (2–4). Since the
timing and level of B7-1 expression is unchanged in B7-
22/2 mice and, likewise, B7-2 expression is unaffected in
B7-12/2 mice (our unpublished data), the difference in
conclusions drawn from the two systems is not likely to be
attributable to alterations in B7 expression in B7-1– or B7-
2–deficient mice. Several factors may have confounded the
results of antibody blocking studies. These include Fc re-
ceptor–mediated effects, inadequate penetration of anti-
bodies in vivo, and varying affinity of the antibodies to
their ligand. Genetic backgrounds may also influence the
respective roles of B7-1 and B7-2 in the induction of EAE.
The relative importance of B7-1 and B7-2 may differ be-
tween MOG-induced EAE in C57BL/6 mice and proteo-
lipid protein (PLP) or myelin basic protein (MBP)-induced
EAE in SJL mice. Induction and level of B7-1 and B7-2
expression may differ on various genetic backgrounds. Ge-
netic analyses have identified chromosomal regions con-
taining the CD28/CTLA-4 and B7-1/B7-2 loci as impor-
tant for the development of EAE (9). Further studies are
needed to determine whether polymorphisms within the
CD28/CTLA-4 or B7-1/B7-2 loci lead to altered expres-
sion of these genes or to altered protein function. Such dif-
Figure 5. EAE induction in wild-type and B7-
1/B7-22/2 mice by adoptive transfer of wild-type
T cells. Wild-type mice were immunized with
MOG 35-55, and draining lymph nodes were har-
vested 10 d later. Lymphocytes were cultured in
MOG 35-55 and IL-12 for 4 d and then transferred
into wild-type (Wt, n 5 16) and B7.1/B7.22/2
(n 5 13) recipients. Data are pooled from two ex-
periments and represent mean clinical score plotted
against time. B7-1/B7-22/2 mice developed signif-
icantly less severe disease compared with wild-type.
*P , 0.05 by the Mann-Whitney test.
Table II. EAE in Wild-type and B7-1/B7-22/2 Mice Induced by Adoptive Transfer of Wild-type MOG-specific T Cells
Clinical EAE Histological EAE
Incidence
Day of
onset
Mean maximal
score Duration (d) Incidence
Meningeal
foci
Parenchymal
foci Total foci
mean 6 SE mean 6 SE mean 6 SE mean 6 SE mean 6 SE mean 6 SE
Wild-type 10/16 14/16
(62.5%) 12.0 6 0.8 2.5 6 0.2 19.0 6 1.0 (87.5%) 40.3 6 9.0 32.9 6 8.9 76.3 6 9.4
B7-1/B7-22/2 8/13 16.0 6 1.7 1.3 6 0.1 8.5 6 1.5 11/13 11.4 6 3.3 2.2 6 0.7 13.6 6 3.8
(61.5%) P , 0.05 P , 0.001 P , 0.001 (84.6%) P , 0.001 P , 0.01 P , 0.001
*All P values are compared with wild-type.739 Chang et al.
ferences in the B7-CD28/CTLA-4 costimulatory pathway
on different genetic backgrounds could contribute to the
relative role of B7-1 versus B7-2 or CD28 in the patho-
genesis of EAE and other autoimmune diseases.
Cytokines play a key role in initiating, propagating, and
regulating tissue-specific autoimmune injury. The role of
cytokines in regulating EAE is complex. Although there is
evidence that Th1 cells that produce proinflammatory cy-
tokines (IFN-g and TNF-a) are critical for the induction
of EAE, direct administration of anti–IFN-g in vivo en-
hanced EAE (10, 11). And although intrathecal injection of
IFN-g induced local inflammation (12), systemic adminis-
tration of IFN-g suppressed EAE development (13). Re-
cent studies using cytokine- or cytokine receptor–deficient
mice suggest that rather than promoting CNS inflamma-
tion, IFN-g and TNF-a may be important in limiting the
extent and duration of EAE. Mice lacking IFN-g or IFN-g
receptor develop more severe MOG-induced EAE than
wild-type littermates (14–16). TNF-a2/2 mice develop se-
vere MOG-induced EAE with extensive inflammation, de-
myelination, and high mortality (17–19). Our results show
that although B7-1/B7-22/2 mice are resistant to MOG-
induced EAE, peripheral T cells from these mice produce
increased levels of IFN-g and TNF-a. Whether resistance
to EAE in B7-1/B7-22/2 mice is due to lack of expansion
of encephalitogenic precursors or to excessive production
of IFN-g and TNF-a is not clear. However, our observa-
tions of increased IFN-g or TNF-a by B7-1/B7-22/2 T
cells and EAE resistance in B7-1/B7-22/2 mice are consis-
tent with studies that report exacerbated EAE in mice lack-
ing IFN-g or TNF-a. (14–19). Our data are also consistent
with studies demonstrating a major defect in Th2 but not
Th1 cytokine production in the absence of both B7-1 and
B7-2 or CD28 (20, 21).
Our results suggest that impaired T cell expansion could,
in part, be responsible for EAE resistance in B7-1/B7-22/2
mice, since it appears that MOG-specific T cells are primed
in these mice but that their expansion is markedly reduced.
However, in addition to controlling T cell expansion, B7
molecules may also be important in regulating migration of
encephalitogenic T cells into the CNS and/or their reacti-
vation within the CNS. The greater proportionate reduc-
tion of parenchymal, as opposed to meningeal, infiltrates in
B7- and CD28-deficient mice compared with those in
wild-type mice also suggests that B7 interactions may affect
inflammatory cell homing to different CNS compartments.
Furthermore, the adoptive transfer experiments demon-
strate for the first time that, in addition to playing a key
role in the initial expansion and differentiation of T cells,
B7 costimulation is required for mediating inflammation
during the effector phase of EAE. The demonstration of a
key role of B7 costimulation in the effector phase of EAE
has important therapeutic implications, since most autoim-
mune diseases are diagnosed after initial responses to the
autoantigens. Our results provide impetus for testing B7
blockade as a therapeutic approach in the effector phase of
human autoimmune diseases.
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